trending Market Intelligence /marketintelligence/en/news-insights/trending/o4zsmvct3rnv69q9nugm0w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Shionogi seeks US, European approval for low blood platelet count drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Shionogi seeks US, European approval for low blood platelet count drug

Shionogi & Co. Ltd. said the U.S. Food and Drug Administration and European Medicines Agency accepted its application for S-888711 to treat thrombocytopenia in patients with chronic liver disease who are at increased risk for bleeding from invasive procedures.

Thrombocytopenia is a common complication of chronic liver disease, characterized by low blood platelet count.

The Japanese company's applications are backed by the results of two phase 3 clinical trials where S-888711, or lusutrombopag, met its main goals of not requiring platelet transfusion or rescue therapy from bleeding and increasing platelet count.

Shionogi's new drug application was granted priority review by the FDA, with the target action date set for Aug. 26.